Literature DB >> 19034460

The evaluation of primary stenting of sirolimus-eluting versus bare-metal stents in the treatment of atherosclerotic lesions of crural arteries.

Aleksander Falkowski1, Wojciech Poncyljusz, Grazyna Wilk, Małgorzata Szczerbo-Trojanowska.   

Abstract

A comparison was made of sirolimus-eluting stents and bare stents as an effective means of treatment of stenosis in crural arteries. Patients were randomly divided into two groups: (1) patients treated with sirolimus-eluting stents and (2) patients treated with bare stents. Each group consisted of 25 patients, and every patient had one stent implanted. All patients showed symptoms of ischemia of the peripheral arteries, classified according to the Rutherford scale into categories 3, 4, and 5. All patients were examined 24 h before and 24 h and 6 months after the intervention. The results were analyzed according to clinical, hemodynamic, and angiographic criteria. Technically, the procedure was successful in 100% of cases, and both groups presented an equal improvement in clinical and hemodynamic parameters. The follow-up angiographic examination demonstrated a significantly lower rate of restenosis among the sirolimus-eluting stent group (4, 16%) versus the bare stent group (19, 76%) (p < 0.001), with lower target lesion revascularization in 3 (12%) versus 14 (56%) (p < 0.05), respectively. Quantitative angiography demonstrated that all variables used to assess restenosis were superior for sirolimus-eluting stents 6 months after intervention: late lumen loss 0.46 +/- 0.72 versus 1.70 +/- 0.94 (p < 0.001) and minimal lumen diameter 2.25 +/- 0.82 versus 0.99 +/- 1.08 (p < 0.001). Results of this study reveal that the use of sirolimus-eluting stents decreases the risk of restenosis in comparison to standard stents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034460     DOI: 10.1007/s00330-008-1225-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  29 in total

Review 1.  Coronary in-stent restenosis - predictors, treatment and prevention.

Authors:  R Hoffmann; G S Mintz
Journal:  Eur Heart J       Date:  2000-11       Impact factor: 29.983

2.  Percutaneous transluminal angioplasty of crural arteries: diabetes and other factors influencing outcome.

Authors:  G Danielsson; U Albrechtsson; L Norgren; P Danielsson; E Ribbe; J Thörne; Z Zdanowski
Journal:  Eur J Vasc Endovasc Surg       Date:  2001-05       Impact factor: 7.069

3.  Percutaneous transluminal angioplasty of infrapopliteal arteries in patients with intermittent claudication: acute and one-year results.

Authors:  Hans Krankenberg; Ina Sorge; Thomas Zeller; Thilo Tübler
Journal:  Catheter Cardiovasc Interv       Date:  2005-01       Impact factor: 2.692

Review 4.  Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials.

Authors:  Laura Mauri; E John Orav; Susana C Candia; Donald E Cutlip; Richard E Kuntz
Journal:  Circulation       Date:  2005-11-01       Impact factor: 29.690

5.  Comparison of sirolimus-eluting vs. bare-metal stents for the treatment of infrapopliteal obstructions.

Authors:  Dierk Scheinert; Mathias Ulrich; Susanne Scheinert; Jacqueline Sax; Sven Bräunlich; Giancarlo Biamino
Journal:  EuroIntervention       Date:  2006-08       Impact factor: 6.534

6.  Mortality over a period of 10 years in patients with peripheral arterial disease.

Authors:  M H Criqui; R D Langer; A Fronek; H S Feigelson; M R Klauber; T J McCann; D Browner
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

7.  Percutaneous transluminal angioplasty for treatment of ''below-the-knee'' critical limb ischemia: early outcomes following the use of sirolimus-eluting stents.

Authors:  M Bosiers; K Deloose; J Verbist; P Peeters
Journal:  J Cardiovasc Surg (Torino)       Date:  2006-04       Impact factor: 1.888

Review 8.  The role of infrapopliteal angioplasty.

Authors:  D Tsetis; A-M Belli
Journal:  Br J Radiol       Date:  2004-12       Impact factor: 3.039

9.  The increasing role of percutaneous transluminal angioplasty in the primary management of critical limb ischaemia.

Authors:  M K Nasr; R J McCarthy; J Hardman; A Chalmers; M Horrocks
Journal:  Eur J Vasc Endovasc Surg       Date:  2002-05       Impact factor: 7.069

10.  A 1 year prospective study of management and outcome of patients presenting with critical lower limb ischaemia.

Authors:  C M H Bailey; S Saha; T R Magee; R B Galland
Journal:  Eur J Vasc Endovasc Surg       Date:  2003-02       Impact factor: 7.069

View more
  12 in total

Review 1.  Endovascular Treatment of Infrapopliteal Peripheral Artery Disease.

Authors:  Ehrin J Armstrong; Kalkidan Bishu; Stephen W Waldo
Journal:  Curr Cardiol Rep       Date:  2016-04       Impact factor: 2.931

Review 2.  Drug-Eluting Balloons and Drug-Eluting Stents in the Treatment of Peripheral Vascular Disease.

Authors:  Jonathan Lindquist; Kristofer Schramm
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

3.  Network meta-analysis of balloon angioplasty, nondrug metal stent, drug-eluting balloon, and drug-eluting stent for treatment of infrapopliteal artery occlusive disease.

Authors:  Yaowen Xiao; Zhong Chen; Yaoguo Yang; Lei Kou
Journal:  Diagn Interv Radiol       Date:  2016 Sep-Oct       Impact factor: 2.630

Review 4.  Does patency matter in patients with critical limb ischemia undergoing endovascular revascularization?

Authors:  Frederic Baumann; Ernst Groechenig; Nicolas Diehm
Journal:  Ann Vasc Dis       Date:  2014-03-15

5.  Implementation of innovative medical technologies in German inpatient care: patterns of utilization and evidence development.

Authors:  Cornelia Henschke; Dimitra Panteli; Marie Dreger; Helene Eckhardt; Susanne Felgner; Hanna Ermann; Hendrikje Lantzsch; Tanja Rombey; Reinhard Busse
Journal:  Implement Sci       Date:  2021-10-30       Impact factor: 7.327

6.  Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-09-01

7.  Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial.

Authors:  Marlon I Spreen; Jasper M Martens; Bettina E Hansen; Bob Knippenberg; Elke Verhey; Lukas C van Dijk; Jean-Paul P M de Vries; Jan-Albert Vos; Gert Jan de Borst; Evert-Jan P A Vonken; Jan J Wever; Randolph G Statius van Eps; Willem P Th M Mali; Hans van Overhagen
Journal:  Circ Cardiovasc Interv       Date:  2016-02       Impact factor: 6.546

8.  Long-Term Follow-up of the PADI Trial: Percutaneous Transluminal Angioplasty Versus Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia.

Authors:  Marlon I Spreen; Jasper M Martens; Bob Knippenberg; Lukas C van Dijk; Jean-Paul P M de Vries; Jan Albert Vos; Gert Jan de Borst; Evert-Jan P A Vonken; Okker D Bijlstra; Jan J Wever; Randolph G Statius van Eps; Willem P Th M Mali; Hendrik van Overhagen
Journal:  J Am Heart Assoc       Date:  2017-04-14       Impact factor: 5.501

9.  Revisiting endovascular treatment in below-the-knee disease. Are drug-eluting stents the best option?

Authors:  Stavros Spiliopoulos; Panagiotis M Kitrou; Elias N Brountzos
Journal:  World J Cardiol       Date:  2018-11-26

Review 10.  The Importance of Patency in Patients with Critical Limb Ischemia Undergoing Endovascular Revascularization for Infrapopliteal Arterial Disease.

Authors:  Frederic Baumann; Christoph Ozdoba; Ernst Gröchenig; Nicolas Diehm
Journal:  Front Cardiovasc Med       Date:  2015-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.